{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T02:52:04Z","timestamp":1786935124544,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Survival rates in patients with non-medullary thyroid carcinoma (NMTC) are high, increasing the possibility to develop a second malignant neoplasm (SMN). Many studies investigated the relationship between increased risk of SMN in NMTC patients treated with radioiodine, but few data are available about the impact of family history (FH) of thyroid cancer on SMN risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the risk of SMN in a large cohort of sporadic and familial NMTC using the standardized incidence ratio (SIR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>We studied 918 NMTC patients (73.9% female patients) followed for a median follow-up of 9 years. In 798\/918 (86.9%) patients, NMTC was sporadic, while the remaining 120 (13.1%) were familial NMTC (FNMTC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 119\/918 (13%) patients with SMN in association with NMTC. NMTCs had an increased risk of SMN when compared to the general population (SIR 2.1, 95% CI 1.7\u20132.5). The rate of SMN for all sites was significantly higher in familial compared to sporadic NMTC (20% versus 11.9%, <jats:italic>p<\/jats:italic> = 0.01), primarily driven by families with more than two affected members. The risk of SMN was remarkably higher for breast cancer, especially in familial cases (SIR 22.03, 95% CI 14.4\u201341.2) compared to sporadic cases (SIR:17, 95% CI 11.9\u201324.6).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>NMTC patients have a higher risk of SMN compared to the general population and this risk is much higher in patients with FNMTC. This observation raises the hypothesis that genetic risk factors for a first cancer may predispose to SMN, especially among individuals with familial clustering of the same or other tumors.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.845954","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T07:29:25Z","timestamp":1646378965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Risk of Second Malignant Neoplasm in Familial Non-Medullary Thyroid Cancer Patients"],"prefix":"10.3389","volume":"13","author":[{"given":"Marco","family":"Capezzone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Sagnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cantara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Fralassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Maino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Forleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Brilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Pilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cartocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0655","article-title":"Second Primary Cancer in Patients With Differentiated Thyroid Cancer: Does Radioiodine Play a Role","volume":"27","author":"Silva-Vieira","year":"2017","journal-title":"Thyroid"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0266","article-title":"Estimation of Second Primary Cancer Risk After Treatment With Radioactive Iodine for Differentiated Thyroid Carcinoma","volume":"27","author":"Corr\u00eaa","year":"2017","journal-title":"Thyroid"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26070","article-title":"Rising Incidence of Second Cancers in Patients With Low-Risk (T1N0) Thyroid Cancer Who Receive Radioactive Iodine Therapy","volume":"117","author":"Iyer","year":"2011","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1448-y","article-title":"Risk of Second Primary Cancer Following Differentiated Thyroid Cancer","volume":"31","author":"Berthe","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33116","article-title":"Nonthyroidal Second Primary Malignancies in Differentiated Thyroid Cancer Patients: Is the Incidence Increased Comparing to the General Population and Could it be a Radioiodine Therapy Consequence","volume":"147","author":"Cappagli","year":"2020","journal-title":"Int J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20876","article-title":"Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History","volume":"35","author":"Sud","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-018-0089-y","article-title":"Impact of Family History of Cancer on Risk and Mortality of Second Cancers in Patients With Prostate Cancer","volume":"22","author":"Chattopadhyay","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky068","article-title":"Familial Risks and Mortality in Second Primary Cancers in Melanoma","volume":"2","author":"Chattopadhyay","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1899","article-title":"Second Primary Cancer After Female Breast Cancer: Familial Risks and Cause of Death","volume":"8","author":"Zheng","year":"2019","journal-title":"Cancer Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01435-x","article-title":"Familial non-Medullary Thyroid Cancer: A Critical Review","volume":"44","author":"Capezzone","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa798","article-title":"Role of Age at Diagnosis in Defining Potential Familial Nonmedullary Thyroid Cancer in Kindreds With Two Affected Members","volume":"106","author":"Capezzone","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02250-3","article-title":"An Update on Familial Nonmedullary Thyroid Cancer","volume":"68","author":"Ammar","year":"2020","journal-title":"Endocrine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2013.0079","article-title":"Familial Nonmedullary Thyroid Carcinoma","volume":"23","author":"Mazeh","year":"2013","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0736","article-title":"Identification of Rare Variants Predisposing to Thyroid Cancer","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111364","article-title":"Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer","volume":"11","author":"Miasaki","year":"2020","journal-title":"Genes (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0010065","article-title":"Cancer as a Complex Phenotype: Pattern of Cancer Distribution Within and Beyond the Nuclear Family","volume":"1","author":"Amundadottir","year":"2004","journal-title":"PloS Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"B19","first-page":"1","article-title":"Italian Cancer Figures, Report 2013: Multiple Tumours","volume":"37","year":"2013","journal-title":"Epidemiol Prev"},{"key":"B20","first-page":"1","article-title":"Statistical Methods in Cancer Research. Volume II\u2013The Design and Analysis of Cohort Studies","author":"Breslow","year":"1987","journal-title":"IARC Sci Publ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple Primary Tumours: Challenges and Approaches, a Review","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-012-0331-6","article-title":"Implementing Cancer Prevention Into Clinical Practice","volume":"27","author":"Cialdella-Kam","year":"2012","journal-title":"J Cancer Educ"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31818d8779","article-title":"Subsequent Malignant Neoplasms in Cancer Survivors","volume":"14","author":"Ng","year":"2008","journal-title":"Cancer J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29025","article-title":"Elevated Risks of Subsequent Primary Malignancies in Patients With Thyroid Cancer: A Nationwide, Population-Based Study in Korea","volume":"121","author":"Cho","year":"2015","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2016.0037","article-title":"Incidence of Nonthyroidal Primary Malignancy and the Association With (131)I Treatment in Patients With Differentiated Thyroid Cancer","volume":"26","author":"Hirsch","year":"2016","journal-title":"Thyroid"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2009","article-title":"Second Primary Cancers in Thyroid Cancer Patients: A Multinational Record Linkage Study","volume":"91","author":"Sandeep","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0244","article-title":"A Systematic Review and Meta-Analysis of Subsequent Malignant Neoplasm Risk After Radioactive Iodine Treatment of Thyroid Cancer","volume":"28","author":"Yu","year":"2018","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/2359-3997000000078","article-title":"Is Radioactive Iodine- 131 Treatment Related to the Occurrence of Non-Synchronous Second Primary Malignancy in Patients With Differentiated Thyroid Cancer","volume":"60","author":"Souza","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14517","article-title":"A Genome-Wide Association Study Yields Five Novel Thyroid Cancer Risk Loci","volume":"8","author":"Gudmundsson","year":"2017","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ng.339","article-title":"Common Variants on 9q22.33 and 14q13.3 Predispose to Thyroid Cancer in European Populations","volume":"41","author":"Gudmundsson","year":"2009","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965","article-title":"The Breast-Thyroid Cancer Link: A Systematic Review and Meta-Analysis","volume":"25","author":"Nielsen","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt280","article-title":"Family History of Cancer and the Risk of Cancer: A Network of Case-Control Studies","volume":"24","author":"Turati","year":"2013","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/000348940611500806","article-title":"Risk of Second Primary Malignancy After Radioactive Iodine Treatment for Differentiated Thyroid Carcinoma","volume":"15","author":"Bhattacharyya","year":"2006","journal-title":"Ann Otol Rhinol Laryngol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.845954\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T07:29:29Z","timestamp":1646378969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.845954\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":33,"alternative-id":["10.3389\/fendo.2022.845954"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.845954","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"article-number":"845954"}}